Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism
- 1 April 2003
- journal article
- clinical trial
- Published by Elsevier BV in Kidney International
- Vol. 63 (4), 1483-1490
- https://doi.org/10.1046/j.1523-1755.2003.00878.x
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial.Nephrology Dialysis Transplantation, 1998
- Calcitriol administration in end-stage renal disease: intravenous or oral?Pediatric Nephrology, 1996
- Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro.JCI Insight, 1996
- Renal OsteodystrophyNew England Journal of Medicine, 1995
- Pathogenesis of Secondary HyperparathyroidismAmerican Journal of Kidney Diseases, 1994
- The spectrum of bone disease in end-stage renal failure—An evolving disorderKidney International, 1993
- Safety and Efficacy of Long-Term Treatment of Secondary Hyperparathyroidism by Low-Dose Intravenous CalcitriolAmerican Journal of Kidney Diseases, 1992
- Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium.JCI Insight, 1989
- Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells.Proceedings of the National Academy of Sciences of the United States of America, 1985
- Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.JCI Insight, 1984